From our survey
A ladder of oversight: depression treatments by FDA status
From approved with a safety program down to off-label at home, each rung compared on the review behind it and what it trades away.
Most comparisons of depression treatments line them up by how fast they work or how they feel. This one lines them up by a different measure: how much regulatory oversight stands behind each one. Think of it as a ladder. At the top are treatments reviewed by the FDA for depression and delivered under strict conditions. At the bottom are options with little formal review for this use.
We built it because oversight clearly matters to people. Of the 443 adults our summer poll heard from in ten Midwest states, 59 percent expected FDA approval to count heavily, or settle the matter, when a depression treatment is new to them, even though most could not name a treatment that has it. Those are the final numbers.
A higher rung does not mean a better treatment for you. It means more formal review of the product for that use. Your own fit is a clinician's call.
Rung 1: Approved, with a required safety program
Esketamine (Spravato). Holder of an FDA approval for hard-to-treat depression, and bound by a Risk Evaluation and Mitigation Strategy that restricts it to certified sites. Staff watch as you use the spray, keep you under observation for two hours or more, and you hand your keys over until the next day. Nothing goes home with you. Brain Recovery Centers describes how Spravato treatment is delivered at this top rung.
What this rung gives you: A formal FDA review of evidence for this specific use, plus mandatory safeguards on every dose.
What it asks of you: Repeated clinic visits, a ride home each time, and usually a prior authorization.
Awareness is the weak spot on this top rung. Of our respondents, 73 percent had not heard the name Spravato before, and 6 percent could explain it.
Rung 2: Approved, prescribed in the usual way
Standard antidepressants. FDA-approved for depression. Prescribed by a clinician, filled at a pharmacy, and taken at home, with follow-up visits.
What this rung gives you: Formal review for depression and broad familiarity among prescribers. Generic versions are usually inexpensive and widely covered.
What it asks of you: Patience, since effects often take weeks, and honesty with your prescriber about side effects. This is also the rung many people have already climbed without enough relief. Our respondents know that rung well: 72 percent reported depression, anxiety, or PTSD in themselves or someone close that standard medication failed to fix.
Rung 3: Cleared device
TMS (transcranial magnetic stimulation). Magnetic pulses from a scalp coil act on the brain's mood circuitry. No medication and no anesthesia. The FDA has cleared TMS systems for adults whose major depression has not eased on antidepressant medication.
What this rung gives you: A formal FDA review through the device pathway, and a drug-free option. We place it on its own rung because clearance and approval are different processes, not because one is less trustworthy.
What it asks of you: Nearly every weekday for a stretch of weeks. Typical complaints are scalp soreness and headache, and clinics screen for the rare risk of seizure.
Interest here is high and awareness low. Our respondents valued a drug-free option at 64 percent, yet 25 percent had any idea what TMS is.
Rung 4: Off-label use of an approved drug, in a clinic
IV ketamine infusions for depression. The approval generic ketamine holds is as an anesthetic, so infusing it for depression is off-label. Infusions are given in a clinic, with staff monitoring the patient during and after.
What this rung gives you: A drug with a long safety record in anesthesia, given under clinical supervision. There is published research on its use for depression.
What it does not give you: An FDA review of this particular use. Practices vary between clinics because there is no single required safety program like the one attached to esketamine. Coverage is often limited, so many patients pay out of pocket.
Rung 5: Off-label, at home, sometimes compounded
At-home ketamine. Often prescribed through telehealth as tablets or lozenges, sometimes made by compounding pharmacies. Compounded drugs are not FDA-approved.
What this rung gives you: Convenience and privacy.
What it does not give you: FDA review of the product for depression, and the in-person monitoring that the higher rungs require. This is the rung where it matters most to ask who makes the product, how it is checked, and who is responsible for your safety.
Off the ladder: psychotherapy
Therapy is not a product, so the FDA does not regulate it. Oversight comes from state licensing of therapists. Structured approaches such as cognitive behavioral therapy have a long evidence base in depression. It belongs in any honest comparison even though it does not fit on this ladder.
How oversight trades off against other priorities
Oversight did not lead when respondents picked two provider priorities. Coverage did, at 85 percent, then proximity at 43 percent; the FDA stamp got 27 percent, speed a smaller 24. Rated alone, coverage was big or deciding for 65 percent.
That lines up with the ladder in an interesting way. The higher rungs tend to be the ones insurers cover for their labeled uses, usually after prior authorization. The lower rungs are more often paid out of pocket. For many people, climbing the ladder and staying within coverage may point in the same direction.
Proximity cuts the other way: the top rung needs a certified site, and many counties lack one.
Using the ladder with your doctor
Bring the ladder to an appointment and ask where a recommended treatment sits on it, and why your doctor thinks that rung makes sense for you. Most respondents would lean on that answer, since 74 percent said a doctor's say-so is what would get them started.
Keep taking current medication while you explore; any change belongs in a plan with your prescriber.
No rung of this ladder matters more than getting through a hard night. With thoughts of suicide, reach 988 by phone or text; the Suicide and Crisis Lifeline picks up at every hour and asks nothing about treatment plans.
Methodology
Pollfish handled fieldwork for survey 395586438 among consumer-panel members and stopped on June 23, 2026, at 443 responses. All respondents were between 18 and 64, residents of Illinois, Kansas, Ohio, Minnesota, Missouri, Indiana, Iowa, Oklahoma, Nebraska or Wisconsin, and each accepted a consent screener. A multi-select percentage counts the portion of the whole sample choosing that answer. Validation is complete; these numbers are final. The publisher initiated and funded the survey.